<DOC>
	<DOCNO>NCT00421473</DOCNO>
	<brief_summary>MalaroneÂ® ( atovaquone/proguanil ) frequently use malaria prophylaxis . Unfortunately , indication certain anti-HIV agent may decrease atovaquone plasma level induction atovaquone metabolism . For travel HIV patient , clinical consequence possible drug drug interaction serious , since diminish exposure anti-malarial drug result suboptimal prophylaxis malaria potential development drug resistant strain Plasmodium falciparum . The purpose study find HIV patient use HAART regimes either lopinavir/ritonavir , atazanavir/ritonavir efavirenz low atovaquone plasma level healthy volunteer single dose atovaquone/proguanil .</brief_summary>
	<brief_title>Drug Interaction Study Between Atovaquone Antiretroviral Agents HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>For healthy volunteer 18 65 year smoke habit &lt; 10 cigarette , 2 cigar 2 pipe BMI 18 30 kg/m2 able willing sign inform consent form subject good ageappropriate health condition subject normal blood pressure pulse rate For HIV patient HIVinfected documented positive HIV antibody test confirm Western Blot . CD4+ &gt; 200 * 10E6 per Liter . 18 65 year BMI 18 30 kg/m2 able willing sign inform consent form use lopinavir/ritonavir , atazanavir/ritonavir efavirenz least 1 month dose 400/100mg bid , 300/100 mg QD , 600 mg QD respectively Exclusion Criteria healthy volunteer : History sensitivity/idiosyncrasy atovaquone/proguanil chemically related compound excipients . Positive HIV test . Positive HbsAg test ( hepatitis B ) positive hepatitis C test . Therapy drug ( two week precede dose ) , except paracetamol . Creatinine clearance &lt; 60 mL/min ( calculate serum creatinine ) Current diarrhoea . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose . Donation blood within 60 day prior first dose . Pregnant female ( confirm HCG test perform less 3 week first dose ) breastfeed female . Abnormal serum transaminase , determine level &gt; 3 time upper limit normal Febrile illness within 3 day first dose Exclusion criterion HIV patient : History sensitivity/idiosyncrasy atovaquone/proguanil chemically related compound excipients . Suspicion nonadherence HIV medication . Current diarrhoea . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . Inability understand nature extent trial procedure require . Pregnant female ( confirm HCG test perform less 3 week first dose ) breastfeed female . Abnormal serum transaminase determine level &gt; 3 time upper limit normal Creatinine clearance &lt; 60 mL/min ( calculate serum creatinine ) . Any change antiretroviral medication within 1 month immediately pre cede dose atovaquone/proguanil . Concomitant use medication interfere atovaquone proguanil pharmacokinetics : anticoagulant , aurothioglucose , chloroquine , cimetidine , fluoxetine , fluvoxamine , metoclopramide , omeprazole , magnesiumtrisilicate , rifabutin , rifampin , tetracycline , typhoid vaccine , topiramate . Use HAART regime contain lopinavir/ritonavir another protease inhibitor NNRTI . Use HAART regime contain atazanavir/ritonavir another protease inhibitor NNRTI . Use HAART regime contain efavirenz one protease inhibitor nevirapine . Active hepatobiliary hepatic disease Alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>Malaria prophylaxis</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>